Industry Focus
Healthcare: ASH 2017's Big Winners And Losers
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:28:35
- Mas informaciones
Informações:
Sinopsis
Celgene and bluebird bio report a stunning success in multiple myeloma, Juno Therapeutics takes it on the chin despite positive data, and Spark Therapeutics suffers in its showdown with BioMarin in hemophilia.
